C3肾小球病与原发性免疫复合物介导MPGN替代终点的Delphi共识
31 条陈述中 29 条达成共识(≥75% 同意),支持蛋白尿减少是保留长期肾功能的重要治疗目标。
要点
- 蛋白尿减少可保留长期肾功能,应作为治疗目标。
- 6 个月内蛋白尿降低≥50% 提示有意义的治疗获益。
- 蛋白尿<1 g/d 与结局改善相关。
核心结论
- 共识支持蛋白尿作为 C3G 和原发性 IC-MPGN 有意义的治疗终点。
研究设计与样本
- 两轮改良 Delphi 流程,基于文献回顾和专家意见,由 4 名欧洲肾脏科医生、1 名加拿大肾脏科医生和 1 名欧洲风湿科医生组成指导委员会制定 31 条陈述。
主要发现
- 31 条陈述中 29 条达成共识(≥75% 同意)。
- 关键共识包括蛋白尿减少可保留长期肾功能且是治疗目标、纵向监测蛋白尿联合其他标志物对指导治疗有价值、6 个月内蛋白尿降低≥50% 提示有意义的治疗获益、蛋白尿<1 g/d 与结局改善相关。
关键数值与推荐
- 共识阈值:≥75% 同意。
- 6 个月内蛋白尿降低≥50% 提示有意义的治疗获益。
- 蛋白尿<1 g/d 与结局改善相关。
临床怎么用
- 在 C3G 和原发性 IC-MPGN 的临床试验与临床管理中,可将蛋白尿降低≥50%(6 个月)和蛋白尿<1 g/d 作为评估治疗获益的参考指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) are rare kidney diseases driven by complement dysregulation. Proteinuria is a commonly used clinical end point in trials involving these conditions. However, its recognition as a validated end point by regulatory bodies remains limited, despite growing evidence supporting its prognostic value as a surrogate biomarker for the development of kidney failure. The aim of this study was to establish consensus on the clinical relevance of proteinuria as a prognostic and treatment end point in C3G and primary IC-MPGN. METHODS: A 2-round modified Delphi process was conducted, informed by literature review and expert input. A steering committee composed of 4 European nephrologists, 1 Canadian nephrologist, and 1 European rheumatologist developed 31 statements covering the following 3 domains: (i) treatment efficacy end points, (ii) current assessment end points, and (iii) the role of proteinuria. Statements formed part of an online survey using a 4-point Likert scale, distributed to a broader panel of nephrologists and kidney pathologists across Europe. RESULTS: Fifty-one and 50 responses were received in rounds 1 and 2. Of the 31 statements, 29 reached consensus (≥ 75% agreement). Key consensus points included the following: (i) reduction in proteinuria preserves long-term kidney function and is a treatment goal; (ii) longitudinal monitoring of proteinuria, alongside other markers is valuable for guiding treatment; (iii) a ≥ 50% proteinuria reduction over 6 months indicates meaningful therapeutic benefit; and (iv) proteinuria < 1 g/d is associated with improved outcomes. CONCLUSION: This study demonstrates consensus supporting proteinuria as a meaningful treatment end point for C3G and primary IC-MPGN.
引用
- Caravaca-Fontán F, Fakhouri F, Licht C, et al. Delphi Consensus on Surrogate End Points in C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Kidney Int Rep. 2025. PMID: 41502799. doi:10.1016/j.ekir.2025.10.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。